We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Mindray Showcases Hematology Innovations at ISLH 2022

By LabMedica International staff writers
Posted on 27 Sep 2022

Mindray (Shenzhen, China) showcased its hematology innovations and academic achievements to medical experts from Europe and around the world at the International Symposium on Technological Innovations in Laboratory Hematology (ISLH 2022) held between September 8-10 in Bologna, Italy. More...

Held annually, the symposium serves as an international platform where the latest technology, new ideas and research findings in laboratory hematology are showcased and shared.

At ISLH 2022, Mindray held a seminar titled "The New Era of Digital Morphology", where Prof. Gina Zini and Prof. Anna Merino, two renowned experts in morphology, presented an evaluation of the performance of its MC-80 digital cell morphology analyzer in detecting onco-hematological diseases by referring to special clinical cases, and how it can help doctors screen and diagnose malignant and non-malignant blood diseases, respectively through high-resolution blood cell images. During the ISLH poster session, 32 posters from Mindray's hematology end-users were presented after stringent evaluation based on unique insights and exceptional academic values, outnumbering all other exhibitors. At its ISLH 2022 booth, Mindray showcased its new MC-80 digital cell morphology analyzer and the BC-700 series hematology analyzer, which attracted much interest from visitors. Mindray's academic strength was also recognized by the ISLH committee which granted the company the "Berend Houwen Travel Award" for outstanding contributions to the industry and excellence in academics.

Before ISLH, Mindray attracted over 700 participants to the HemaTalk Italy 2022 Global Live Event. Dr. Ramon Simon-Lopez from Mindray IVD Scientific Research and Medical Affairs, noted that the company has been utilizing its global resources to build a learning and exchange platform for global medical experts and empower the future of laboratory medicine. The attendees held an online conversation with Mindray’s R&D team to discuss the future of laboratory hematology and the latest trends in translating clinical research results into practice. A Q&A session followed where the attendees had their most important questions answered by Mindray’s experts.

Related Links:
Mindray 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.